XML 62 R51.htm IDEA: XBRL DOCUMENT
v3.19.1

Related Party Transactions (Details Narrative) $ / shares in Units, $ in Thousands |  |  |  |  |  |  | 1 Months Ended | 8 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 26, 2017 USD ($) | Nov. 17, 2017 | Nov. 07, 2017 | Aug. 11, 2017 USD ($) | Jul. 09, 2017 USD ($) | Jun. 23, 2017 USD ($) | Jul. 31, 2018 USD ($) | Apr. 30, 2018 | Dec. 31, 2017 USD ($) $ / shares shares | Dec. 31, 2018 USD ($) Products $ / shares shares
Common stock issued | shares |  |  |  |  |  |  |  |  | 6,000,000 | 17,607,928
Common stock par value per share | $ / shares |  |  |  |  |  |  |  |  | $ 0.001 | $ 0.001
Number of stock options issued to purchase common stock | shares |  |  |  |  |  |  |  |  |  | 225,000
Stock-based compensation expense |  |  |  |  |  |  |  |  | $ 1,761 | $ 1,850
Payment of research and development expense |  |  |  |  |  |  |  |  | 3,930 | $ 5,627
Credit agreement term |  | 10 years | 10 years |  |  |  |  |  |  |
Restricted Stock [Member] |  |  |  |  |  |  |  |  |  |
Number of stock options issued to purchase common stock | shares |  |  |  |  |  |  |  |  |  | 218,980
Research and Development Expense [Member] |  |  |  |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  |  |  |  |  | 26 | $ 80
Harrow Health Inc [Member] |  |  |  |  |  |  |  |  |  |
Common stock issued | shares |  |  |  |  |  |  |  |  |  | 3,500,000
Common stock par value per share | $ / shares |  |  |  |  |  |  |  |  |  | $ 0.001
Number of products | Products |  |  |  |  |  |  |  |  |  | 2
Harrow Health Inc [Member] | Stock Option [Member] |  |  |  |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  |  |  |  |  | 112 | $ 51
Harrow Health Inc [Member] | Common Stock [Member] |  |  |  |  |  |  |  |  |  |
Restricted stock award forfeited | shares |  |  |  |  |  |  |  |  |  | 20,000
Percentage of restricted stock and option vested |  |  |  |  |  |  |  | 100.00% |  |
Harrow Health Inc [Member] | Restricted Stock [Member] |  |  |  |  |  |  |  |  |  |
Number of restricted common stock issued for services | shares |  |  |  |  |  |  |  |  |  | 1,500,000
Number of stock options issued to purchase common stock | shares |  |  |  |  |  |  |  |  |  | 130,000
Stock-based compensation expense |  |  |  |  |  |  |  |  | $ 1,370 | $ 970
Harrow Health Inc [Member] | Licensing Agreement [Member] |  |  |  |  |  |  |  |  |  |
Related party transaction |  |  |  |  |  |  | $ 50 |  |  |
Harrow Health Inc [Member] | Research and Development Expense [Member] |  |  |  |  |  |  |  |  |  |
Related party transaction | $ 50 |  |  |  |  |  |  |  |  |
Harrow Health Inc [Member] | Patents [Member] |  |  |  |  |  |  |  |  |  |
Related party transaction |  |  |  |  |  |  |  |  |  | $ 50
Royalty fee percentage |  |  |  |  |  |  |  |  |  | 6.00%
Eyemax [Member] |  |  |  |  |  |  |  |  |  |
Related party transaction |  |  |  | $ 250 |  |  |  |  |  |
Payment of research and development expense |  |  |  | 250 |  |  |  |  |  |
Sale of product expense |  |  |  | $ 500 |  |  |  |  |  |
Related party transaction date |  |  |  | Aug. 11, 2017 |  |  |  |  |  |
Percentage of royalty fee |  |  |  | 10.00% |  |  |  |  |  |
Credit agreement term |  |  |  | 10 years |  |  |  |  |  |
Andersen Pharma LLC [Member] |  |  |  |  |  |  |  |  |  |
Related party transaction |  |  |  |  | $ 750 |  |  |  |  |
Payment of research and development expense |  |  |  |  | 750 |  |  |  |  |
Sale of product expense |  |  |  |  | $ 750 |  |  |  |  |
Related party transaction date |  |  |  |  | Jul. 09, 2017 |  |  |  |  |
Percentage of royalty fee |  |  |  |  | 50.00% |  |  |  |  |
Credit agreement term |  |  |  |  | 5 years |  |  |  |  |
Selenix LLC [Member] |  |  |  |  |  |  |  |  |  |
Related party transaction |  |  |  |  |  | $ 1,500 |  |  |  |
Payment of research and development expense |  |  |  |  |  | 1,500 |  |  |  |
Sale of product expense |  |  |  |  |  | $ 1,000 |  |  |  |
Related party transaction date |  |  |  |  |  | Jun. 23, 2017 |  |  |  |
Percentage of royalty fee |  |  |  |  |  | 50.00% |  |  |  |
Credit agreement term |  |  |  |  |  | 10 years |  |  |  |

X
- Definition Credit agreement term. + References No definition available. + Details
Name: | ETON_CreditAgreementTerm
Namespace Prefix: | ETON_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of products. + References No definition available. + Details
Name: | ETON_NumberOfProducts
Namespace Prefix: | ETON_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Restricted stock and stock options vested. + References No definition available. + Details
Name: | ETON_PercentageOfRestrictedStockAndStockOptionsVested
Namespace Prefix: | ETON_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty fee percentage. + References No definition available. + Details
Name: | ETON_RoyaltyFeePercentage
Namespace Prefix: | ETON_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 + Details
Name: | us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of transactions with related party during the financial reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 + Details
Name: | us-gaap_RelatedPartyTransactionAmountsOfTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in CCYY-MM-DD format. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionDate
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07.1(c)) -URI http://asc.fasb.org/extlink&oid=114873854&loc=SL114874292-224272 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 + Details
Name: | us-gaap_RevenueFromRelatedParties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Gross number of share options (or share units) granted during the period. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares related to Restricted Stock Award forfeited during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ETON_HarrowHealthIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ETON_LicensingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ETON_EyemaxLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ETON_AndersenPharmaLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ETON_SelenixLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |